The KEYNOTE-630 Trial: A Phase 3 Study of Adjuvant Pembrolizumab in High -Risk Locally Advanced (LA) Cutaneous Squamous Cell Carcinoma (cSCC)

被引：0
|
作者：
Schenker, M. [1 ]
Klochikhin, M. [2 ]
Kirtbaya, D. [3 ]
Mother, L. [4 ]
Gschnell, M. [5 ]
Robert, C. [6 ,7 ]
Meyer, N. [8 ,9 ]
Flatz, L. [10 ]
Dalle, S. [11 ]
Beylot-Barry, M. [12 ]
Eigentler, T. [13 ,14 ,15 ]
Silverman, R. Kloss [16 ]
Gumuscu, B. [16 ]
Yuan, J. [16 ]
Bratland, A. [17 ]
机构：
[1] Univ Med & Pharm Craiova, Craiova, Romania
[2] Yaroslavl Reg SBIH Clin Oncol Hosp, Yaroslavl, Russia
[3] Minist Hlth Krasnodar Region, Oncol Dispensary 2, Soci, Russia
[4] Univ Lille, CHRU Lille, Lille, France
[5] Univ Hosp Marburg UKGM, Skin Tumor Ctr, Dermatol Clin, Marburg, Germany
[6] Univ Paris Saclay, Le Kremlin Bicetre, France
[7] Gustave Roussy, Villejuif, France
[8] Inst Univ Canc, Toulouse, France
[9] CHU Toulouse, Inserm UMR 1037 CRCT, Toulouse, France
[10] Eberhard Karts Univ Titbingen, Titbingen, Germany
[11] Lyon Univ, HCL Canc Inst, Canc Res Ctr Lyon, Lyon, France
[12] Univ Bordeaux, Hop St Andre, Bordeaux, France
[13] Charith Univ Med, Berlin, Germany
[14] Free Univ Berlin, Berlin, Germany
[15] Humboldt Univ, Berlin, Germany
[16] Merck & Co Inc, Rahway, NJ USA
[17] Oslo Univ Hosp, Oslo, Norway
来源：
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS | 2024年 / 118卷 / 05期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
245
引用
收藏
页码：E81 / E82
页数：2
相关论文
共 50 条
  • [1] KEYNOTE-630: Phase 3 study of pembrolizumab as adjuvant treatment in high-risk locally advanced (LA) cutaneous squamous cell carcinoma (cSCC)
    Lee, Jenny
    Dzienis, Marcin
    Schmults, Chrysalyne
    Schneker, Michael
    Bratland, Ase
    Klochikhin, Mikhail
    Gifoni, Markus
    Kirtbaya, Dmitry
    Rivera-Diaz, Julian
    Chipman, Mitchell
    Geiger, Jessica L.
    Chang, Anne L. S.
    Daniels, Gregory A.
    Cohen, Ezra E. W.
    Yao, Lili
    Gumuscu, Burak
    Yuan, Jianda
    Guminski, Alexander
    Bowers, Elani
    [J]. ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2022, 18 : 234 - 235
  • [2] Phase 3 KEYNOTE-630 study of adjuvant pembrolizumab in high-risk locally advanced cutaneous squamous cell carcinoma
    Schenker, Michael
    Klochikhin, Mikhail
    Kirtbaya, Dmitry
    Mortier, Laurent
    Gschnell, Martin
    Robert, Caroline
    Meyer, Nicolas
    Flatz, Lukas
    Dalle, Stephane
    Beylot-Barry, Marie
    Eigentler, Thomas
    Silverman, Rachel Kloss
    Gumuscu, Burak
    Yuan, Jianda
    Bratland, Aase
    [J]. CLINICAL CANCER RESEARCH, 2023, 29 (18)
  • [3] Adjuvant pembrolizumab or placebo in patients with high-risk, locally advanced cutaneous squamous cell carcinoma: Phase 3 KEYNOTE-630
    Chang, Anne Lynne S.
    Daniels, Gregory A.
    Cohen, Ezra E.
    Ge, Joy Yang
    Gumuscu, Burak
    Swaby, Ramona F.
    Geiger, Jessica L.
    [J]. CANCER RESEARCH, 2020, 80 (16)
  • [4] Adjuvant pembrolizumab versus placebo in high-risk locally advanced cutaneous squamous cell carcinoma: The phase 3 KEYNOTE-630 study
    Schenker, Michael
    Klochikhin, Mikhail
    Bratland, Ase
    Kirtbaya, Dmitry
    Guminski, Alexander
    Dzienis, Marcin
    Schmults, Chrysalyne
    Ge, Joy Y.
    Yuan, Jianda
    Lee, Jenny
    [J]. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2022, 87 (03) : AB135 - AB135
  • [5] KEYNOTE-630: phase 3 study of adjuvant pembrolizumab versus placebo in patients with high-risk, locally advanced cutaneous squamous cell carcinoma
    Geiger, Jessica
    Daniels, Gregory
    Cohen, Ezra
    Ge, Joy Yang
    Gumuscu, Burak
    Swaby, Ramona
    Chang, Anne Lynn
    [J]. JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2019, 7
  • [6] KEYNOTE-630: Phase 3 study of adjuvant pembrolizumab versus placebo in patients with high risk, locally advanced cutaneous squamous cell carcinoma.
    Geiger, Jessica Lyn
    Daniels, Gregory A.
    Cohen, Ezra E. W.
    Ge, Joy Yang
    Gumuscu, Burak
    Swaby, Ramona F.
    Chang, Anne Lynn S.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [7] KEYNOTE-629: Phase 2 study of pembrolizumab for recurrent/metastatic or locally advanced unresectable cutaneous squamous cell carcinoma (cSCC).
    Grob, Jean Jacques
    Gonzalez, Rene
    Basset-Seguin, Nicole
    Schachter, Jacob
    Vornicova, Olga
    Bauman, Jessica Ruth
    Grange, Florent
    Meyer, Nicolas
    Piulats, Josep M.
    Zhang, Eric
    Gumuscu, Burak
    Swaby, Ramona F.
    Hughes, Brett Gordon Maxwell
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [8] Phase 2 study of pembrolizumab (pembro) for locally advanced (LA) or recurrent/metastatic (R/M) cutaneous squamous cell carcinoma (cSCC): KEYNOTE-629.
    Hughes, Brett G. M.
    Munoz-Couselo, Eva
    Mortier, Laurent
    Bratland, Ase
    Gutzmer, Ralf
    Roshdy, Osama
    Gonzalez Mendoza, Rene
    Schachter, Jacob
    Arance, Ana
    Grange, Florent
    Meyer, Nicolas
    Joshi, Abhishek
    Billan, Salem
    Zhang, Pingye
    Gumuscu, Burak
    Swaby, Ramona F.
    Grob, Jean-Jacques
    [J]. CANCER RESEARCH, 2021, 81 (13)
  • [9] Pathologic response rates to neoadjuvant pembrolizumab in locally advanced (LA) resectable cutaneous squamous cell carcinoma (cSCC)
    Amatore, Florent
    Sridharan, Shaum
    Karunamurthy, Arivarasan
    Wang, Hong
    Patel, Ravi
    Pugliano-Mauro, Melissa
    Kim, Seungwon
    Choudry, Mohammad Haroon Asif
    Pingpank, James F., Jr.
    Holtzman, Matthew Peter
    Duvvuri, Uma Maheswari
    Ferris, Robert L.
    Luke, Jason J.
    Kirkwood, John M.
    Najjar, Yana G.
    Pullara, Filippo
    Chennubhotla, Chakra
    Zarour, Hassane M.
    Davar, Diwakar
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [10] KEYNOTE-629: Phase 2 trial of pembrolizumab in patients (pts) with recurrent or metastatic cutaneous squamous cell carcinoma (cSCC)
    Licitra, L.
    Siu, L.
    Cohen, E.
    Zhang, P.
    Gumuscu, B.
    Swaby, R.
    Harrington, K.
    [J]. ANNALS OF ONCOLOGY, 2017, 28
12345